TX-PHILLIPS-66
19.7.2022 15:02:13 CEST | Business Wire | Pressemeddelelse
Phillips 66 (NYSE: PSX) og H2 Energy Europe ("H2 Energy") meddelte i dag, at de har indgået en 50-50 joint venture-aftale med henblik på etablering og drift af et netværk af brinttankstationer og skabelsen af et grønt brintøkosystem i Tyskland, Østrig og Danmark.
JET H2 Energy Austria GmbH (JET H2 Energy), som udgør joint venture-aftalen mellem datterselskaberne Phillips 66 Limited og H2 Energy Europe SA, forener Phillips 66's store ekspertise inden for detailhandel med H2 Energys erfaringer og ekspertise inden for brint. JET H2 Energy bliver en central aktør i branchen og vil sætte skub i udviklingen af brint som brændstof i Europa. Det nye selskab planlægger at etablere cirka 250 brinttankstationer inden 2026.
"Det er vores mål at gøre brint til en førende energibærer inden for emissionsfri mobilitet. Vi vil skabe ligevægt i de involverede aktørers interesser i hele brintværdikæden og skabe et bæredygtigt brintøkosystem,” udtaler Olaf Borbor, administrerende direktør for JET H2 Energy.
"Phillips 66 er med stor succes til stede på detailmarkedet i Europa med sit brand JET® . H2 Energy har en dokumenteret track record inden for skabelsen af et vellykket grønt brintøkosystem i Schweiz. Parternes kompetencer supplerer derfor hinanden ideelt i den næste fase i udviklingen af brintøkonomien."
JET H2 Energy vil søge og udvælge steder (greenfield-udvikling, JET® og kundesteder), etablere og drive brinttankstationer til både tunge og lette køretøjer og personbiler (FCEV'er), forsyne brinttankstationerne med grøn brint og opbygge relationer med kunder og originaludstyrsproducenter.
JET H2 Energy vil drage fordel af sit tætte samarbejde med Hyundai Hydrogen Mobility, der er eksklusiv europæisk forhandler af Hyundai Xcient-brintbrændselscellelastbilen.
Ledelsesteamet består af Olaf Borbor (CEO), Markus Wolf (CFO) og Jonas Erdmann (Commercial Manager). Det tyske hovedkvarter er baseret i Hamborg.
Phillips 66 Limited er en kombineret energiproduktions- og logistikvirksomhed hjemhørende i Storbritannien. Virksomheden er et datterselskab under og 100 % ejet af Phillips 66. Phillips 66 har med flere end 1.000 JET® -stationer en stærk tilstedeværelse på markedet i Europa og via joint venture-samarbejdet Coop Mineraloel AG et voksende netværk til optankning af brint i Schweiz.
H2 Energy Europe med hovedsæde i Schweiz er et joint venture mellem selskabet Trafigura Pte Ltd., der handler med råvarer, og H2 Energy Holding AG, en førende brintleverandør i Europa med investeringer i produktion, distribution og anvendelse af grøn brint. H2 Energy var gennem sine tilknyttede selskaber den første til at udvikle og levere brintbrændselscellelastbiler til kommercielle brugere og skabe et grønt brintbrændstof-økosystem i Schweiz.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220718005806/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum